JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival

  • 0Medical Faculty, Radiation Therapy Clinic, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle (Saale), Germany.
Strahlentherapie Und Onkologie : Organ Der Deutschen Röntgengesellschaft ... [et Al] +

|

September 6, 2024

|

September 6, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Increasing serum selenium levels during lung cancer radiotherapy correlate with improved survival. Selenium may serve as a predictive marker for overall survival in non-small cell lung cancer (NSCLC) patients.

Area Of Science

  • Oncology
  • Trace Element Research
  • Radiotherapy

Background

  • Lung cancer is a significant global health concern.
  • Selenium, a trace element, shows potential as a prognostic marker and therapeutic agent in cancer.
  • Understanding selenium's role in lung cancer treatment is crucial.

Purpose Of The Study

  • To investigate the association between serum selenium levels and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) undergoing radiotherapy.
  • To determine if changes in selenium levels during treatment predict patient outcomes.
  • To explore selenium's potential as a predictive biomarker in NSCLC.

Main Methods

  • Ninety-nine patients with histologically confirmed NSCLC were enrolled.
  • Serum selenium levels were measured using total-reflection X-ray fluorescence (TXRF) spectroscopy at three time points: before irradiation (t0), after 20 Gy (t1), and at the end of radiotherapy (t2).
  • Kaplan-Meier analysis and adjusted Cox regression models were used to assess overall survival in relation to selenium levels and changes over time, with further subgroup analysis for metastatic disease.

Main Results

  • A significant change in selenium concentration between t0 and t1 was observed for the entire group (HR=0.5, p=0.03) and in patients with metastatic NSCLC (HR=0.3, p=0.04).
  • Baseline selenium levels were associated with OS in non-metastasized NSCLC (HR=0.3, p=0.04).
  • Increased serum selenium levels during radiotherapy (t0 to t1) were linked to improved OS (HR=0.46, p=0.05).

Conclusions

  • Rising serum selenium levels during radiotherapy appear to be a significant predictor of improved overall survival in NSCLC patients.
  • Serum selenium may function as a predictive factor for OS in this patient population.
  • Further research is warranted to explore the therapeutic potential of selenium supplementation in NSCLC.

Keywords: